Typhoid and paratyphoid fever in travellers

被引:154
作者
Connor, BA
Schwartz, E [1 ]
机构
[1] Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel
[2] Cornell Univ, Weill Med Coll, New York, NY USA
[3] New York Ctr Travel & Trop Med, New York, NY USA
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1016/S1473-3099(05)70239-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Enteric fever-a more inclusive term for typhoid fever and paratyphoid fever-is a systemic infection caused by Salmonella enterica, including S enterica serotype Typhi (S typhi) and serotype Paratyphi (S paratyphi). In developed countries there have been two major changes in the pattern of the disease: a marked decline in its incidence and its characterisation as a predominantly travel-associated disease. The risk to travellers appears to vary by geographic region visited, with travel to the Indian subcontinent accounting for the greatest travel risk. Although the most common cause of enteric fever is S typhi, the incidence of disease caused by S paratyphi among travellers may be more important, since the available vaccines only protect against S typhi. Descriptions of the clinical presentation in travellers are scarce but severe complications and death are rare, probably due to rapid access to readily available medical care. Drug resistance reflects the situation in endemic countries, and shows a steady increase in multidrug-resistance patterns. Currently, the recommendation for first-line therapy is ceftriaxone and, where isolates have been found to be quinolone sensitive, fluoroquinolones can still be given. Preventive measures are educating travellers about hygiene precautions and vaccination. With an increase in multidrug-resistant strains, a more effective vaccine for S typhi and S paratyphi is urgently needed.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [21] TYPHOID HEPATITIS
    KHOSLA, SN
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1990, 66 (781) : 923 - 925
  • [22] Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
    Klugman, KP
    Koornhof, HJ
    Robbins, JB
    LeCam, NN
    [J]. VACCINE, 1996, 14 (05) : 435 - 438
  • [23] Lester A, 1994, Ugeskr Laeger, V156, P3770
  • [24] Lighton L L, 1999, Commun Dis Public Health, V2, P145
  • [25] The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam
    Lin, FYC
    Ho, VA
    Bay, PV
    Nguyen, TTT
    Bryla, D
    Thanh, TC
    Khiem, HB
    Trach, DD
    Robbins, JB
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2000, 62 (05) : 644 - 648
  • [26] The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children
    Lin, FYC
    Ho, VA
    Khiem, HB
    Trach, DD
    Bay, PV
    Thanh, TC
    Kossaczka, Z
    Bryla, DA
    Shiloach, J
    Robbins, JB
    Schneerson, R
    Szu, SC
    Lanh, MN
    Hunt, S
    Trinh, L
    Kaufman, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) : 1263 - 1269
  • [27] MELTZER E, IN PRESS J TRAVEL ME
  • [28] MELTZER E, IN PRESS AM J TROP M
  • [29] Typhoid fever in the United States, 1985-1994 -: Changing risks of international travel and increasing antimicrobial resistance
    Mermin, JH
    Townes, JM
    Gerber, M
    Dolan, N
    Mintz, ED
    Tauxe, RV
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (06) : 633 - 638
  • [30] A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water
    Mermin, JH
    Villar, R
    Carpenter, J
    Roberts, L
    Samaridden, A
    Gasanova, L
    Lomakina, S
    Bopp, C
    Hutwagner, L
    Mead, P
    Ross, B
    Mintz, ED
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) : 1416 - 1422